Genetic variants and cognitive functions in patients with brain tumors.
SNP
brain tumors
cognitive
genes
polymorphisms
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
09 10 2019
09 10 2019
Historique:
pubmed:
28
5
2019
medline:
7
8
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
Patients with brain tumors treated with radiotherapy (RT) and chemotherapy (CT) often experience cognitive dysfunction. We reported that single nucleotide polymorphisms (SNPs) in the APOE, COMT, and BDNF genes may influence cognition in brain tumor patients. In this study, we assessed whether genes associated with late-onset Alzheimer's disease (LOAD), inflammation, cholesterol transport, dopamine and myelin regulation, and DNA repair may influence cognitive outcome in this population. One hundred and fifty brain tumor patients treated with RT ± CT or CT alone completed a neurocognitive assessment and provided a blood sample for genotyping. We genotyped genes/SNPs in these pathways: (i) LOAD risk/inflammation/cholesterol transport, (ii) dopamine regulation, (iii) myelin regulation, (iv) DNA repair, (v) blood-brain barrier disruption, (vi) cell cycle regulation, and (vii) response to oxidative stress. White matter (WM) abnormalities were rated on brain MRIs. Multivariable linear regression analysis with Bayesian shrinkage estimation of SNP effects, adjusting for relevant demographic, disease, and treatment variables, indicated strong associations (posterior association summary [PAS] ≥ 0.95) among tests of attention, executive functions, and memory and 33 SNPs in genes involved in: LOAD/inflammation/cholesterol transport (eg, PDE7A, IL-6), dopamine regulation (eg, DRD1, COMT), myelin repair (eg, TCF4), DNA repair (eg, RAD51), cell cycle regulation (eg, SESN1), and response to oxidative stress (eg, GSTP1). The SNPs were not significantly associated with WM abnormalities. This novel study suggests that polymorphisms in genes involved in aging and inflammation, dopamine, myelin and cell cycle regulation, and DNA repair and response to oxidative stress may be associated with cognitive outcome in patients with brain tumors.
Sections du résumé
BACKGROUND
Patients with brain tumors treated with radiotherapy (RT) and chemotherapy (CT) often experience cognitive dysfunction. We reported that single nucleotide polymorphisms (SNPs) in the APOE, COMT, and BDNF genes may influence cognition in brain tumor patients. In this study, we assessed whether genes associated with late-onset Alzheimer's disease (LOAD), inflammation, cholesterol transport, dopamine and myelin regulation, and DNA repair may influence cognitive outcome in this population.
METHODS
One hundred and fifty brain tumor patients treated with RT ± CT or CT alone completed a neurocognitive assessment and provided a blood sample for genotyping. We genotyped genes/SNPs in these pathways: (i) LOAD risk/inflammation/cholesterol transport, (ii) dopamine regulation, (iii) myelin regulation, (iv) DNA repair, (v) blood-brain barrier disruption, (vi) cell cycle regulation, and (vii) response to oxidative stress. White matter (WM) abnormalities were rated on brain MRIs.
RESULTS
Multivariable linear regression analysis with Bayesian shrinkage estimation of SNP effects, adjusting for relevant demographic, disease, and treatment variables, indicated strong associations (posterior association summary [PAS] ≥ 0.95) among tests of attention, executive functions, and memory and 33 SNPs in genes involved in: LOAD/inflammation/cholesterol transport (eg, PDE7A, IL-6), dopamine regulation (eg, DRD1, COMT), myelin repair (eg, TCF4), DNA repair (eg, RAD51), cell cycle regulation (eg, SESN1), and response to oxidative stress (eg, GSTP1). The SNPs were not significantly associated with WM abnormalities.
CONCLUSION
This novel study suggests that polymorphisms in genes involved in aging and inflammation, dopamine, myelin and cell cycle regulation, and DNA repair and response to oxidative stress may be associated with cognitive outcome in patients with brain tumors.
Identifiants
pubmed: 31123752
pii: 5498070
doi: 10.1093/neuonc/noz094
pmc: PMC6784270
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1297-1309Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197402
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuroscience. 2009 Nov 24;164(1):72-87
pubmed: 19446012
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
Nat Genet. 2018 Sep;50(9):1318-1326
pubmed: 30104760
Acta Oncol. 2008;47(5):809-24
pubmed: 18568480
Neuron. 2005 Feb 3;45(3):345-51
pubmed: 15694321
Clin Cancer Res. 2012 Nov 1;18(21):5961-71
pubmed: 22977194
Prog Brain Res. 2000;126:325-41
pubmed: 11105655
J Neural Transm (Vienna). 2013 Mar;120(3):497-506
pubmed: 23322030
J Am Stat Assoc. 2009 Sep 1;104(487):1015-1028
pubmed: 20333278
Genes Dev. 2009 Jul 1;23(13):1571-85
pubmed: 19515974
Neuro Oncol. 2016 Oct;18(10):1425-33
pubmed: 27091610
Cancer Treat Rev. 2012 Oct;38(6):737-59
pubmed: 22387145
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Neurobiol Aging. 2003 Nov;24(7):921-6
pubmed: 12928051
Carcinogenesis. 2016 Jan;37(1):30-8
pubmed: 26521212
J Alzheimers Dis. 2013;36(4):749-57
pubmed: 23669301
Nat Neurosci. 2004 Mar;7(3):221-8
pubmed: 14966521
Biometrics. 2016 Jun;72(2):584-95
pubmed: 26575519
J Clin Oncol. 2013 Jun 10;31(17):2182-8
pubmed: 23650422
Biol Psychiatry. 2011 Jun 15;69(12):e113-25
pubmed: 21531388
Neuropsychopharmacology. 2014 Sep;39(10):2357-65
pubmed: 24713612
J Cogn Neurosci. 2017 Feb;29(2):245-253
pubmed: 27647283
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
Brain. 2015 Jun;138(Pt 6):1548-67
pubmed: 25805644
J Clin Oncol. 2006 Mar 10;24(8):1305-9
pubmed: 16525186
Expert Opin Biol Ther. 2008 Oct;8(10):1561-70
pubmed: 18774923
Mutat Res. 2007 Jan 3;614(1-2):24-36
pubmed: 16879837
Lancet Oncol. 2016 Mar;17(3):e97-e108
pubmed: 26972863
Int J Biochem Cell Biol. 2008;40(10):1971-8
pubmed: 18468478
Adv Genet. 2008;62:1-32
pubmed: 19010252
Clin Cancer Res. 2015 Jul 15;21(14):3340-6
pubmed: 25904748
Neurology. 2014 Jul 22;83(4):320-7
pubmed: 24944262
PLoS One. 2011;6(10):e24588
pubmed: 22046233
Alzheimers Dement (N Y). 2017 Jun;3(2):254-261
pubmed: 28993814
Am J Manag Care. 2016 Jun;22(6 Suppl):s159-70
pubmed: 27356025
Alzheimers Dement. 2016 Jun;12(6):719-32
pubmed: 27179961
Lancet Oncol. 2019 Feb;20(2):e92-e102
pubmed: 30723041
J Cogn Neurosci. 2014 Feb;26(2):395-407
pubmed: 24144248
Mol Neurobiol. 2017 Mar;54(2):1314-1325
pubmed: 26843108
Springerplus. 2016 Sep 29;5(1):1688
pubmed: 27733989
Neurobiol Aging. 2012 May;33(5):1017.e1-15
pubmed: 22054870
Int J Radiat Biol. 2011 Feb;87(2):115-29
pubmed: 21067298
Mol Psychiatry. 2006 Sep;11(9):867-77, 797
pubmed: 16786032
Neuroreport. 2006 Jun 26;17(9):913-6
pubmed: 16738487
Ann Neurol. 2011 Jan;69(1):47-64
pubmed: 21280075
Trends Cogn Sci. 2004 Jul;8(7):325-35
pubmed: 15242692